Developing software IVO for clinical, laboratory, therapeutic and cost data collection for Sickle Cell Anemia

Main Article Content

Andréia Insabralde de Queiroz Cardoso
Maria Lúcia Ivo
Marcos Antonio Ferreira Júnior
Luiz Fernando Delboni Lomba
Caroline Neris Ferreira Sarat
Carolina Mariano Pompeo
Mayk Penze Cardoso
Maurício Duailibi Neto
Raphael Viana de Paula Leite
Jander Santos Souza
Felipe Machado Mota

Abstract

The challenge to improve the treatment of Sickle Cell Disease (SCD) is to plan for managers and health professionals, as well as to estimate the necessary costs. To this end, research should be developed to support the health area, with emphasis on the development of software that complements data collection. For these reasons, the objective of this study is to describe the development of software for the collection of cost information and clinical, laboratory and therapeutic data of patients with SCD, which can be used in the future by other areas of health. This is an experimental and applied research focused on technological production. The applied process model was incremental and followed the steps of communication, planning, modeling and development.  The first version is in the testing phase and presents the record format, does not require internet connection, can interact with Windows®, Linux® or MacOS® operating systems and encrypt data for storage. In the next increments, the customization of the fields with a broad structure for data collection; data export in spreadsheet format for use in external tools; creation of customized reports and central database stands out.

Downloads

Download data is not yet available.

Article Details

How to Cite
Cardoso, A. I. de Q., Ivo, M. L. ., Ferreira Júnior, M. A., Lomba, L. F. D., Sarat, C. N. F. ., Pompeo, C. M. ., Cardoso, M. P. ., Duailibi Neto, M. ., Leite, R. V. de P. ., Souza, J. S. ., & Mota, F. M. . (2019). Developing software IVO for clinical, laboratory, therapeutic and cost data collection for Sickle Cell Anemia. International Journal for Innovation Education and Research, 7(12), 28-35. https://doi.org/10.31686/ijier.vol7.iss12.1858
Section
Articles

References

[1] R.D. Cançado, J.A.A. Jesus. Sickle cell disease in Brazil. Revista Brasileira de Hematologia e Hemoterapia. vol. 29, no. 3, pp.203-6, 2007.

[2] S. Chakravorty, T.N. Williams. Sickle cell disease: a neglected chronic disease of increasing global health importance. Archives of Disease in Childhood, no. 100, pp.48-53, 2015.

[3] G.J. Kato, M.H. Steinberg, M. T. Gladwin. Intravascular hemolysis and the pathophysiology of sickle cell disease. Journal of Clinical Investigation, vol. 127, no. 3, pp750-60, 2017.

[4] Brasil. Ministério da Saúde. Portaria n. 05, de 19 de fevereiro de 2018. Clinical Protocol and Therapeutic Guidelines for Sickle Cell Disease. Diário Oficial da União, Brasília, DF, n. 36 - Seção 1, p. 75 de 22 de fev. de 2018.

[5] Brasil. Comissão Nacional de Incorporação e de Tecnologia no SUS - CONITEC. Clinical Protocol and Therapeutic Guidelines for Sickle Cell Disease. Recommendation Report. 2016.

[6] L.V. Parise, N. Berliner. Sickle cell disease: challenges and progress. Blood, vol. 127, no. 7, pp.789, 2016.

[7] O.M.R. Araújo, M.L. Ivo, M.A. Ferreira Junior, E.R.J.C. Pontes, I.M.G.P. Bispo, E.C.L. Oliveira. Sobrevida e mortalidade em usuários e não usuários de hidroxiureia com doença falciforme. Revista Latino Americana de Enfermagem, vol. 23, no. 1, pp. 67–73, 2015.

[8] L.M. Bou-Maroun, F.Meta, C.J. Hanba, A.D. Campbell, G.A. Yanik. An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes. Pediatric Blood & Cancer, vol.65, no.1, pp.1-7, 2018.

[9] C.N.F. Sarat, M.B. Ferraz, M.A. Ferreira Júnior, R.A.C. Corrêa Filho, A.S. Souza, A.I.Q. Cardoso, M.L. Ivo. Prevalence of sickle cell disease in adults with delayed diagnosis. Acta Paulista de Enfermagem, vol. 32, no. 2, pp. 202-9, 2019.

[10] C. Wang, S.O. Oyeku, Z. Luo, S.L. Boulet, S.T. Miller, J.F. Casella, for the Baby Hug Investigators. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics, vol. 132, no.4, pp.677-83, 2013.

[11] T.L. Kauf, T.D. Coates, L. Huazhi, N. Mody-Patel, A.G. Hartzema. The cost of health care for children and adults with sickle cell disease. American Journal of Hematology, vol. 84, no. 6, pp. 323-7, 2009.

[12] D.J. Sperandio, Y.D.M. Évora. Nursing care planning: proposal for a software prototype. Revista Latino Americana de Enfermagem, vol.13, no.6, pp.937-43, 2005.

[13] I.M. Pereira, D. Bonfin, H.H.C. Peres, R.F. Góes, R.R. Gaidzinski. Mobile application for data collection in health research. Acta Paulista de Enfermagem. 2017; 30(5):479-88.

[14] V. Kannan, J.S. Fish, J.M. Mutz, A.R. Carrington, K. Lai, L.A. Davis, J.E. Youngblood, M.R. Rauschuber, K.A. Flores, E.J. Sara, D.G. Bhat, D.L. Willett. Rapid development of specialty population registries and quality measures from electronic health record data. An Agile Framework. Methods Information in Medicine, vol.99, no. 56, pp. e74-e83, 2017.

[15] R. S. Pressman. Engenharia de Software: uma abordagem profissional. Porto Alegre: AMGH, 2011.

[16] Brasil. Lei nº 13.709, de 14 de agosto de 2018. Dispõe sobre a proteção de dados pessoais e altera a Lei nº 12.965, de 23 de abril de 2014 (Marco Civil da Internet). Brasília, 14 ago. 2018.

Most read articles by the same author(s)